The Fifth International Conference

CHALLENGES FOR EFFICIENT HEALTH CARE IN CENTRAL AND EASTERN EUROPE
PRESENTATIONS

Using HTA for making legitimate reimbursement decisions in health care Wija Oortwijn PhD, Partner at ECORYS NL Rotterdam, The Netherlands
HTA as advisory tool for investors – MedInvest Scanner databases Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland
Central and Eastern Europe - Diversity to tame, Market Access potential to unveil Norbert Wilk, Arcana Institute, Poland
Managed Entry Agreements in China: Current Status and Lessons for Central and Eastern Europe Angela Yu MSc, London School of Economics, UK
Real world evidence for real world challenges Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK
Patient registries as a tool for improvement in the quality of treatment and for appropriate planning and allocation of resources Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia
Pharmaceutical Policy in MICs – Challenges and Priorities Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank
Pragmatic Reimbursement Decision Making Framework – A Key for Resolving Reimbursement Impasse in SerbiaDávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary
Western European markets for biosimilar drugs; worth differentiation Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden
Access to innovation – where is Serbia today? Bojan Trkulja MD, Managing Director at INOVIA, Serbia
Challenges associated with high prices of new cancer medicines; potential ways forward for CEE countries based on HTA principles Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden
Why are Orphan Drugs different? – Achieving sustainable access for orphan drugs Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany
Targeted therapies in oncology – a Serbian pharmacoeconomic perspective Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands
Session SFE SFUS - 7th Serbian Congress of Pharmacy
Friday 12th October 2018, Crowne Plaza Hotel, Belgrade, Serbia
SFUS
HEALTH CARE DECISION MAKING FROM THE PHARMACOECONOMIC PERSPECTIVE
Is Belgrade the New Berlin?
APRIL 6, 2017
Vogue
No city makes you feel more like a New Yorker than Belgrade. In Belgrade, people don’t walk, they amble; lunch spans the course of 3 or 4 hours; and drinks are sipped, never knocked back. Despite the slow pace of life, there’s still an unmistakable energy that bursts through the city.
Preliminary Program


The preliminary program for the conference "THE VALUE OF INNOVATION IN DECISION MAKING" is now available. Use the link above or access from the menu in the top right.
VI International SFE SFUS Conference
2nd June 2017, Belgrade, hotel Metropol, Serbia.

The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia (SFE SFUS) is organising its Sixth International Conference with the topic:
"THE VALUE OF INNOVATION IN DECISION MAKING"
Fifth International Conference - Speakers
9th and 10th of October 2015 Belgrade, hotel Metropol
SFE SFUS
Prof. dr Brian Godman PhD, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, UK; Karolinska Institute, Sweden

Wija Oortwijn PhD, Partner at ECORYS NL, The Netherlands

Krzysztof Landa MD, President at MedInvest Scanner Ltd M.I.S., Poland

Mark Parker MSc, Health Economics Unit, University of Liverpool Management School, UK

Angela Yu MSc, London School of Economics, UK

Timothy Johnston, Program Leader for Inclusive Growth and Human Development, Southeast Europe, Europe and Central Asia Region, World Bank

Dávid Dankó PhD, Managing Director at Ideas & Solutions, Hungary

Dr. Günter Harms, Market Access and Public Affairs Director, Shire, Germany

Vanesa Benkovic MSc, Senior HTA and health research consultant, Croatia

Bojan Trkulja MD, Managing Director at INOVIA, Serbia

Tanja Novakovic MSc Pharm, President of Pharmacoeconomics Section, Serbia, Representative of Chamber of Commerce and Industry of Serbia


Jovan Mihajlovic, MSc Pharm, Unit of Pharmacoepidemiology & Pharmacoeconomics, Department of Pharmacy, University of Groningen, The Netherlands

Livio Garattini, Mario Negri Institute, Milano, Italija

Jakub Adamski, Arcana Institute, Poland

Alan Haycox, MSc, Health Economics Unit, University of Liverpool Management School, UK

Norbert Wilk, Arcana Institute, Poland

Neven Lovrinov, MSc Pharm, Terminal d.o.o., Croatia

ARE WE READY FOR BIOSIMILARS?
Belgrade, 28th April 2015, hotel Crowne Plaza
The Pharmacoeconomics Section of the Pharmaceutical Association of Serbia
The objectives of the conference are:

• present the characteristics of biopharmaceutical medicines and biosimilars,

• understanding the nature of biopharmaceutical and biosimilar regulations,

• share clinical experience with biological medications and more generally

• exchanging experiences and knowledge with experts from the region and international stage.
Managed Introduction of new medicines
11 – 13 May 2015 - Warsaw, Poland
PIPERSKA workshop co-organised with the Agency for HTA & Tariff System in Poland and WHO Europe
This course is primarily intended for healthcare
professionals involved with enhancing the rational use
of medicines especially new medicines
Fifth Adriatic and Fourth Croatian Congress of Pharmacoeconomics and Outcomes Research
Šibenik, Croatia, from 23rd to 26th April 2015.
Section for Pharmacoeconomics and Outcomes Research of the Croatian Society for Clinical Pharmacology and Therapeutics, Croatian Medical Association
This year focus will be on the following subjects: 'The role and impact of pharmaceutical industry on the general economy in countries in the region' and 'The need to adapt the model for health technology assessment in countries with high risk of sustainability of healthcare financing in order to ensure transparency and competitiveness'.
PATIENTS REGISTERS IN ORDER TO IMPROVE THE QUALITY OF CARE AND REDUCE THE COSTS OF TREATMENT
5th of February 2015 Crowne Plaza Hotel, Belgrade, SERBIA
SFUS Pharmacoeconomics Section
The purpose of the Conference is to:
• Introduce and present the importance and value of patient registries,
• Introduce health outcomes and treatment outcomes reported by patients,
• Exchange experiences across the countries that used data of patients registers in the
pharmacoeconomic analysis
• Introduce the examples of special agreements (Risk sharing, Pay per Performance)
HTA for Healthcare Quality Assurance
December 15th-16th, 2014, Kraków, Poland
CEESTAHC 9th International Symposium Evidence-Based Health Care 2014